Università degli Studi - Policlinico di Tor Vergata
Welcome,         Profile    Billing    Logout  
 22 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cantonetti, Maria
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
VENDITTI, Adriano
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Maurillo, Luca
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
Principe, Ilaria Del
No trials found
Principe, Maria Ilaria Del
No trials found
Cefalo, Maria Giovanna
No trials found
Arcese, Giorgio
No trials found
Franceschini, Luca
No trials found
Principe, Del
No trials found

Download Options